Gryphon Financial Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $212K | Sell |
8,800
-4,404
| -33% | -$115K | 0.02% | 374 |
|
|
2026
Q1 | $371K | Buy |
13,204
+3,899
| +42% | +$104K | 0.04% | 257 |
|
|
2025
Q4 | $232K | Buy |
9,305
+1,117
| +14% | +$28.2K | 0.02% | 316 |
|
|
2025
Q3 | $209K | Sell |
8,188
-363
| -4% | -$8.96K | 0.02% | 311 |
|
|
2025
Q2 | $207K | Sell |
8,551
-4,979
| -37% | -$116K | 0.03% | 298 |
|
|
2025
Q1 | $343K | Sell |
13,530
-11,583
| -46% | -$303K | 0.05% | 202 |
|
|
2024
Q4 | $666K | Sell |
25,113
-3,891
| -13% | -$106K | 0.1% | 124 |
|
|
2024
Q3 | $839K | Buy |
29,004
+7,906
| +37% | +$231K | 0.11% | 108 |
|
|
2024
Q2 | $590K | Sell |
21,098
-789
| -4% | -$21.7K | 0.09% | 146 |
|
|
2024
Q1 | $607K | Sell |
21,887
-5,055
| -19% | -$140K | 0.1% | 134 |
|
|
2023
Q4 | $861K | Buy |
26,942
+8,194
| +44% | +$248K | 0.15% | 98 |
|
|
2023
Q3 | $622K | Sell |
18,748
-7,040
| -27% | -$249K | 0.14% | 79 |
|
|
2023
Q2 | $946K | Sell |
25,788
-2,455
| -9% | -$95.6K | 0.2% | 61 |
|
|
2023
Q1 | $1.15M | Sell |
28,243
-308
| -1% | -$13.3K | 0.26% | 50 |
|
|
2022
Q4 | $1.46M | Buy |
28,551
+169
| +0.6% | +$8.1K | 0.35% | 37 |
|
|
2022
Q3 | $1.24M | Sell |
28,382
-2,547
| -8% | -$124K | 0.31% | 44 |
|
|
2022
Q2 | $1.62M | Buy |
30,929
+3
| +0% | +$153 | 0.39% | 34 |
|
|
2022
Q1 | $1.6M | Sell |
30,926
-8,450
| -21% | -$438K | 0.33% | 43 |
|
|
2021
Q4 | $2.33M | Buy |
39,376
+13,453
| +52% | +$667K | 0.44% | 32 |
|
|
2021
Q3 | $1.11M | Buy |
25,923
+4,934
| +24% | +$219K | 0.25% | 57 |
|
|
2021
Q2 | $806K | Buy |
20,989
+509
| +2% | +$19.8K | 0.18% | 60 |
|
|
2021
Q1 | $742K | Buy |
20,480
+164
| +0.8% | +$5.82K | 0.17% | 66 |
|
|
2020
Q4 | $748K | Sell |
20,316
-660
| -3% | -$24.2K | 0.19% | 65 |
|
|
2020
Q3 | $731K | Buy |
20,976
+535
| +3% | +$18.8K | 0.22% | 55 |
|
|
2020
Q2 | $634K | Sell |
20,441
-114
| -0.6% | -$3.87K | 0.2% | 54 |
|
|
2020
Q1 | $637K | Sell |
20,555
-1,174
| -5% | -$40K | 0.23% | 49 |
|
|
2019
Q4 | $807K | Sell |
21,729
-790
| -4% | -$28.1K | 0.21% | 52 |
|
|
2019
Q3 | $768K | Buy |
22,519
+1,299
| +6% | +$47.2K | 0.22% | 50 |
|
|
2019
Q2 | $872K | Sell |
21,220
-518
| -2% | -$20.6K | 0.25% | 45 |
|
|
2019
Q1 | $876K | Sell |
21,738
-11,149
| -34% | -$446K | 0.26% | 45 |
|
|
2018
Q4 | $1.28M | Buy |
32,887
+11,225
| +52% | +$466K | 0.33% | 59 |
|
|
2018
Q3 | $906K | Buy |
21,662
+8,466
| +64% | +$326K | 0.27% | 44 |
|
|
2018
Q2 | $454K | Sell |
13,196
-193
| -1% | -$6.59K | 0.21% | 42 |
|
|
2018
Q1 | $450K | Buy |
13,389
+1,638
| +14% | +$56.3K | 0.23% | 40 |
|
|
2017
Q4 | $404K | Buy |
+11,751
| New | +$401K | 0.23% | 43 |
|
Other funds holding PFE
Gryphon Financial Partners's PFE Position: Q2 2026 in Review
Gryphon Financial Partners reduced its Pfizer (PFE) stake by 33% in Q2 2026, selling an estimated $115K and leaving 8,800 shares worth $212K. The position accounts for 0.02% of the portfolio, ranked #374.
Gryphon Financial Partners first reported a position in PFE in Q4 2017 and has held it in 35 quarters since. The position peaked at $2.33M in Q4 2021. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Gryphon Financial Partners held 8,800 shares of Pfizer worth $212K as of Q2 2026.
- Gryphon Financial Partners sold 4,404 Pfizer shares in Q2 2026, an estimated $115K.
- Pfizer made up 0.02% of Gryphon Financial Partners's portfolio in Q2 2026, its #374 holding.
- Gryphon Financial Partners first reported a position in Pfizer in Q4 2017 and has held it in 35 quarters since.
- Gryphon Financial Partners's Pfizer position peaked at $2.33M in Q4 2021.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Gryphon Financial Partners's 13F filing for Q2 2026, filed 5 Aug 2026.